PNC-27™️ 40 MG

Target. Investigate. Advance.

Experience advanced molecular oncology research with PNC-27™️ 40 MG, an experimental peptide investigated for its potential interaction with cancer-cell membrane targets and p53-related anticancer mechanisms.

PNC-27 has attracted scientific interest because laboratory research suggests a selective interaction involving HDM2/MDM2 expressed on certain cancer-cell membranes, making it an intriguing compound for experimental cancer-biology research.

---

The Science of Targeted Peptide Research

PNC-27 — 40 MG

PNC-27 is a synthetic peptide derived from a segment associated with the p53 tumor-suppressor protein, combined with a membrane-penetrating sequence.

Preclinical studies have explored its potential ability to interact with HDM2/MDM2 on the membranes of certain malignant cells and disrupt membrane integrity.

Research interest includes:

• Cancer-cell membrane biology
• p53-related molecular pathways
• HDM2/MDM2 interactions
• Selective cytotoxicity mechanisms
• Tumor-cell signaling
• Experimental peptide-oncology platforms

The research focus: Target recognition + membrane interaction + selective cytotoxicity research + molecular oncology.

---

Key Research Areas

• Investigated for selective cancer-cell targeting mechanisms
• Studied in p53-related oncology research
• Explored for HDM2/MDM2 membrane interactions
• Investigated for cancer-cell membrane disruption
• Supports research into peptide-based anticancer strategies
• Studied across experimental tumor-cell models
• Provides a platform for advanced molecular oncology research

---

Crafted for Advanced Research

Designed for laboratory research focused on:

• Cancer biology
• Tumor-cell membrane mechanisms
• p53 pathways
• HDM2/MDM2 molecular interactions
• Selective cytotoxicity
• Experimental oncology
• Peptide-based molecular research

---

Product Details

PNC-27

Advanced Molecular Oncology Research Peptide
Total: 40 MG

• PNC-27 (40 MG): p53 • HDM2/MDM2 • Cancer-Cell Interaction Research

---

Scientific Perspective

Laboratory and preclinical studies have reported that PNC-27 can interact with HDM2/MDM2 associated with the membranes of certain cancer cells, with subsequent membrane disruption observed in experimental systems.

These findings have made PNC-27 scientifically interesting as a potential model for investigating selective peptide-based anticancer mechanisms.

However, PNC-27 remains an experimental research peptide. Current evidence does not establish it as a proven cancer treatment, and adequate clinical evidence in humans regarding efficacy, dosing, safety, pharmacokinetics, and long-term outcomes is lacking.

---

Research & Handling

PNC-27 should be approached as an experimental laboratory research compound.

It should not be presented as a treatment, cure, or alternative to established cancer therapy. Any oncology-related medical decisions should remain under the supervision of qualified oncology professionals.

---

Why Choose Stayfit Pharma

When quality matters, precision defines the difference.

• 99%+ purity research peptides
• Manufactured under strict quality standards
• Advanced formulations for research applications
• Premium-grade ingredients and quality control

---

PNC-27™️ 40 MG
Advanced Molecular Oncology Research Peptide
Target • Investigate • Advance